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A B S T R A C T
The standardisation process consisted of determining tumour marker levels in all relevant population groups which
are connected with the biology of the marker in normal and tumourous cells. This makes clinical application possible.
ProGRP serum levels were measured in 273 healthy subjects, 176 patients with benign diseases and tumours, 200 with
small cell lung cancer (SCLC), 294 with non-small cell lung cancer (NSCLC), 21 with carcinoid tumour, 93 with undif-
ferentiated lung cancer, 35 with mixed SCLC-NSCLC, and 189 with other malignancies. ProGRP levels in patients with
SCLC and SCLC-NSCLC were significantly higher than in all the other groups (p = 5.4 ´ 10–3). Moreover, in SCLC pa-
tients ProGRP levels significantly correlate with the extent of the disease and the patients’ smoking habit. The cut-off
level of ProGRP for SCLC is 65.89 pg/mL in the Croatian population. It is based on 96.8% specificity in benign diseases
which cause problems in differential diagnosis. The sensitivity of ProGRP was 85% at the time of SCLC diagnosis.
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Introduction
Lung cancer is the most common cancer in the world
today (12.6% of all new cancers, 17.8% cancer deaths).
Almost 99% of lung tumours are carcinomas. There are
two main subtypes: small cell lung carcinoma (SCLC)
and non-small cell lung cancer (NSCLC), which are trea-
ted differently. According to the data of lung cancer inci-
dence, SCLC comprises about 20% of all cases. SCLC is
divided into limited and extensive stage disease, and is
the most aggressive type of lung cancer1.
The lungs of healthy individuals contain cells with
different excretion products and various uptake and ami-
dated products decarboxylation abilities. Such traits en-
able cells to recognise lung tumours of neuroendocrine
origin that is also SCLC.
Gastrin releasing peptides (GRP) are neuroendocrine
molecules present in SCLC cells. GRP stimulates growth
in 20–60% of SCLC probably through autocrine growth
stimulation since GRP works through GRP receptors,
which belong to the superfamily of receptors linked to
the G-protein2. These receptors are present in the cells of
human lung cancer of all histological types, as well as in
smokers’ bronchial epithelia implying the role of GRP in
early pathogenesis3,4. Pro-gastrin releasing peptides
(ProGRP) are a stable GRP product, neuroendocrine
molecules released in the sera of SCLC patients. There
are three types of ProGRP molecules found in human
SCLC cells having identical carboxyl-terminal regions
and a different number of residues5,6,7. Since the half-life
of GRP is only two minutes, it has been impossible to de-
velop a clinically applicable method for its detection in
sera. Instead, a recombinant ProGRP (31–98) with a re-
gion common to all the three types of previously cloned
human ProGRP molecules was synthesised5, and the
ELISA immunoassay was developed8.
It was previously considered that only the amidated
forms of GRP are biologically active through either an
autocrine or a paracrine pathway, but the most recent
findings suggest that non-amidated forms of GRP also
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play the same role in growth stimulation and tumour cell
proliferation. Non-amidated forms, such as ProGRP, are
found in the tumour cells and sera of SCLC patients. The
potential of ProGRP as a tumour marker in early SCLC
diagnosis is enormous, but its clinical application re-
quires standardisation according to a referent population
of healthy subjects and benign diseases. Therefore, the
aim of this research is to determinate the ProGRP cut-off
value encompassing all relevant population data. In a
broader context, high-quality direct medical care de-
mands population specific databases, which include re-
cords on the largest possible number of diagnostic pa-
rameters. Some of the results of this study have pre
-viously been reported in the form of an abstract9 and a
PhD thesis10.
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TABLE 1
DEMOGRAPHICS AND CLINICAL CHARACTERISTICS OF PATIENTS WITH A MALIGNANCY
N %
Small cell lung carcinoma 200 100
Disease extent(Limited/Extensive) 73/127 36.5/63.5
Risk factor(Smokers/Former smokers/Nonsmokers) 119/17/64 59.5/8.5/32
Male/female 159/41 79.5/20.5
Mean age ± SD 63 ± 9
Non-small cell lung carcinoma 294 100
AD/SQC/LCC/LCNE 117/92/27/10 39.8/31.3/9.2/3.4




Mean age ± SD 63 ± 9
Carcinoid tumour 21 100
Typical carcinoid 6 28.6
Atypical carcinoid 8 33.3
Undifferentiated carcinoid 7 38.1
Male/female 12//9 57.1/42.9
Mean age ± SD 63 ± 10
Undifferentiated lung carcinoma 93 100
Male/female 54/39 58.1/41.9
Mean age ± SD 63 ± 10






Mean age ± SD 64 ± 8
Other malignant lung and pleura tumour 48 100
Tumour of the mediastinum 31 64.6
Mesothelioma 10 20.8
Lymphoproliferative tumours 7 14.6
Male/female 32/16 66.7/33.3
Mean age ± SD 57 ± 15
Metastases to the lung 91 100
Male/female 59/32 64.8/35.2
Mean age ± SD 61 ± 11
Malignant tumour of the other organ 50 100
Male/female 25/25 50/50
Mean age ± SD 60 ± 12
SCLC – small cell lung carcinoma, NSCLC – non-small cell lung carcinoma, SQC – squamous cell carcinomas, AD – adenocarcinomas,
LCC – large cell carcinomas, LCNE – large cell neuroendocrine carcinoma
Subjects and Methods
The sample comprised 200 SCLC patients, 294
NSCLC patients, 21 with carcinoid tumour, 93 with un-
differentiated lung carcinoma, 35 with mixed SCLC and
NSCLC, 48 with other malignant lung and pleura tu-
mours, 91 with metastases to the lung, 50 with malig-
nant tumours of other organs, 39 with benign lung and
mediastinal tumours, 7 with benign tumours of other or-
gans, and 130 with benign diseases of the lung and other
organs (Tables 1, 2). Patient samples were collected con-
secutively. There were 273 healthy subjects. The applied
standard clinical methods were reference standards for
establishing the presence or absence of malignant or be-
nign diseases of the lung. All patients with single pulmo-
nary nodules underwent clinical examination, fiberoptic
bronchoscopy and histological typing, chest X-rays, a
computed tomography scan of the chest and brain, and a
computed tomography scan of the upper abdomen. If in
SCLC extensive disease symptoms were detected, a bone
scan and biopsy of the bone marrow, liver, lymph nodes,
skin and ICTP tumour marker were also conducted.
All blood samples were centrifuged after venipunc-
ture. ProGRP levels were determined from either fresh
or frozen (–20 °C) sera using an ELISA kit manufactured
by Advanced Life Science Institute Inc. from Japan. The
assay followed the principle of a two-step sandwich en-
zyme immunoassay with a 96-well microtiter plate, and
was performed according to the manufacturer’s instruc-
tions.
In order to compare ProGRP levels in the sera of dif-
ferent groups of patients and healthy control subject a
Kruskal-Wallis ANOVA and Mann-Whitney U-test were
also conducted using Statistika 6.0 software package
(Statsoft, USA). Any value of p<0.05 was considered sta-
tistically significant. The receiver operating characteris-
tic (ROC) curve was used to determine of the cut-off
value using MedCalc v. 9.2.1.0 (MedCalc Software, Bel-
gium).
Results
The patients were classified according to their histo-
logical type and the characteristics that may influence
ProGRP specificity and sensitivity at the time of diagno-
sis. The levels of ProGRP were measured in 11 groups of
benign and malignant diseases (Tables 1, 2). The sub-
groups were defined according to their histological type,
and the clinical or pathological stage of the diseases in all
the groups.
The distribution of ProGRP tumour marker values in
the studied population showing the mean, median and
interquartile ranges, and 95th percentile are given ac-
cording to the main groups and subgroups in Tables 3
and 4. In healthy individuals or in patients suffering
from benign diseases and tumours of the lung or other
organs, possibly causing problems in differential diagno-
sis, the values of ProGRP were low.
In patients with SCLC the median and interquartile
ranges, and 95th percentile of the level of ProGRP were
significantly higher than in all the other groups (615.72,
130.91–1754.8, 8253.82 pg/mL). Extremely high levels of
ProGRP have been detected more frequently in SCLC,
especially in the extensive stage. Besides SCLC, very
high levels of ProGRP were observed in the mixed tu-
mour types SCLC-NSCLC, SCLC-large cell lung carci-
noma (LCC), SCLC-squamous cell lung carcinoma (SQC)
and SCLC-adenocarcinoma (AD). The 95th percentile
showed higher marker levels in large cell neuroendocrine
lung carcinoma (LCNE), typical and atypical carcinoid
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TABLE 2
CHARACTERISTICS OF HEALTHY SUBJECTS AND PATIENTS WITH BENIGN DISEASES
N %
Benign lung and mediastinal tumours 39 100
Male/female 26/13 66.7/33.3
Mean age ± SD 59 ± 11
Benign tumours of the other organs 7 100
Male/female 3/4 42.9/57.1
Mean age ± SD 59 ± 9
Benign disease of the lung and other organs 130 100
Cronic obstructive pulmonary diseases 12 9.2
Tuberculosis 7 5.4
Pneumonia 26 20
Other benign lung diseases 79 60.8
Benign disease other organs 6 4.6
Male/female 87/43 66.9/33.1
Mean age ± SD 60 ± 14
Healthy subjects 273 100
Male/female 150/123 54.9/45.1
Mean age ± SD 49 ± 12
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TABLE 3












SCLC 200 2230.14 615.72 130.91 1754.80 8253.82
NSCLC 294 433.03 24.95 11.85 40.98 428.74
C 21 218.86 23.19 10.58 60.38 1000.00
UNDIF LC 93 56.06 43.35 21.62 64.50 119.64
SCLC-NSCLC 35 1198.46 368.89 50.67 1182.82 8253.82
OMLPT 48 24.16 23.48 12.87 32.67 47.62
ML 91 34.36 34.06 20.88 42.88 68.01
MTO 50 46.36 17.86 8.95 32.72 78.76
BTLM 39 25.22 20.02 11.22 35.11 60.95
BTO 7 33.18 36.14 0.10 60.65 84.99
BDO 6 55.69 39.62 15.24 106.89 132.69
BDL 124 29.23 27.06 12.06 39.75 63.86
H 273 18.10 15.41 0.16 25.16 55.15
SCLC – small cell lung carcinoma, NSCLC – non -small cell lung carcinoma, C – carcinoid, UNDIF LC – undifferentiated lung carci-
noma, OMLPT – other malignant lung and pleura tumour, ML – metastases to the lung, MTO – malignant tumour of the other organ,
BTLM – benign lung and mediastinal tumors, BTO – benign tumours of the other organs, BDO – benign disease other organs, BDL –
benign disease of the lung, healthy, 25th – 25th percentile, 75th – 75th percentile, 95th – 95th percentile


























































Fig. 1. Receiver operating characteristics (ROC) curves comparing the level of ProGRP in subjects without a malignant disease (speci-
ficity) and small cell lung carcinoma patients (sensitivity). a) Healthy (n=273), benign disease of the lung and other organs (n=130),
and small cell lung carcinoma patients (n=200). The area under the ROC curve was 0.947, standard error 0.0113, 95% confidence in-
terval between 0.926 and 0.964, significance level p (area=0.5) 0.0001. b) Patients with benign diseases of the lung (n=124), benign
lung and mediastinal tumours (n=39) and small cell lung carcinoma patients (n=200). The area under the ROC curve was 0.934, stan-
dard error 0.0131, 95% confidence interval between 0.904 and 0.958, significance level p (area=0.5) 0.0001. c) Patients with non-small
cell lung carcinoma (n=294) and small cell lung carcinoma patients (n=200). The area under the ROC curve was 0.899, standard error
0.0156, 95% confidence interval between 0.870 and 0.925, significance level p (area=0.5) 0.0001. d) Patients with metastases to the lung
(n=91) and small cell lung carcinoma (n=200). The area under the ROC curve was 0.920, standard error 0.0155, 95% confidence inter-
val between 0.882 and 0.948, significance level p (area=0.5) 0.0001.
tumour (TC, AC), undifferentiated NSCLC and squa-
mous cell lung carcinoma (SQC). In NSCLC extremely
high levels were rarely measured. The median and inter-
quartile ranges in 294 NSCLC patients were 24.95 pg/mL
and 11.85–40.98 pg/mL, respectively.
There was a highly significant difference in ProGRP
levels found in the sera of all the studied groups (Krus-
kal-Wallis ANOVA, p=10–4). The Mann-Whitney U-test
showed significant differences in the levels of ProGRP
between SCLC, the mixed SCLC-NSCLC type and the pa-
tients in all the other 11 groups (p=10–4 to p=5.4 ´ 10–3).
Significant differences have also been found between pa-
tients with undifferentiated lung cancer and metastases
to the lung in comparison to the other groups, with the
exception of patients with carcinoid tumours and benign
tumours. The differences are also significant between
NSCLC and SCLC patients, SCLC-NSCLC, undifferenti-
ated lung cancer and patients with metastases to the
lung (Table 5). Kruskal-Wallis ANOVA showed signifi-
cant differences between all the 29 histological sub-
groups (p=10–4). The Mann-Whitney U-test was used for
comparison between the 15 subgroups in the most signif-
icant groups (Table 6). Moreover, the comparison be-
tween SCLC extensive disease stage and the other sub-
groups also showed significant differences, with the only
exception of patients with SCLC-AD and SCLC-LCC.
The same result was also observed amongst subjects with
a limited SCLC disease with the exception of 6 subgroups
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TABLE 4












LD 73 691.38 182.17 68.49 539.93 4925.63
ED 127 3114.63 1000.00 288.09 2805.81 12880.89
AD 117 37.44 25.88 11.03 36.76 140.16
SQC 92 831.35 24.49 12.11 42.42 428.74
LCC 27 88.90 16.00 4.25 38.24 57.95
LCNE 10 1835.55 58.40 33.80 1754.80 8253.82
UNDIF NSCLC 44 580.59 21.90 9.04 44.45 1000.00
AD-LCC/SQC 4 36.14 42.71 27.20 45.09 46.35
TC 6 502.09 41.79 19.37 73.78 2835.72
AC 8 185.01 39,42 9.65 190.90 1000.00
UNDIF C 7 14.78 11,89 5.38 29.83 32.72
UNDIF LC 93 56.06 43.35 21.62 64.50 119.64
SCLC-AD 4 1899.74 987.42 238.81 3560.68 5596.00
SCLC-SQC 8 419.21 305.93 19.61 861.97 978.55
SCLC-LCC 6 1857.90 638.16 146.16 1451.50 8253.82
SCLC-NSCLC 17 1167.43 304.87 53.93 1182.82 8253.82
TM 31 22.17 24.66 11.91 32.49 43.87
MES 10 24.38 22.70 14.48 39.59 57.95
LT 7 32.66 30.15 15.90 42.28 79.34
ML 91 34.36 34.06 20.88 42.88 68.01
MTO 50 46.36 17.86 8.95 32.72 78.76
BTLM 39 25.22 20.02 11.22 35.11 60.95
BTO 7 33.18 36.14 0.10 60.65 84.99
COPD 12 28.31 20.83 11.00 44.66 72.62
TB 7 21.64 27.09 0.10 35.48 47.52
P 26 33.12 24.56 14.05 49.27 80.79
OBLD 79 28.76 27.87 11.89 38.84 60.76
BDO 6 55.69 39.62 15.24 106.89 132.69
SCLC – small cell lung carcinoma, ED – extensive disease SCLC, LD – limited disease SCLC, AD – adenocarcinomas, LCC – large cell
carcinomas, LCNE – large cell neuroendocrine carcinoma, UNDIF – undifferentiated, NSCLC – non-small cell lung carcinoma, SQC –
squamous cell carcinomas, AC – atypical carcinoid, TC – typical carcinoid, C – carcinoid, UNDIF LC – undifferentiated lung carci-
noma, TM – tumour of the mediastinum, MES – mesothelioma, LT – lymphoproliferative tumours, ML – metastases to the lung, MTO
– malignant tumour of the other organ, BTLM – benign lung and mediastinal tumours, BTO – benign tumours of the other organs,
COPD – cronic obstructive pulmonary diseases, TB – tuberculosis, P – pneumonia, OBLD – other benign lung disease, BDO – benign
disease other organs, 25th – 25th percentile, 75th – 75th percentile, 95th – 95th percentile.
(LCNE, TC, SCLC-AD, SCLC-LCC, SCLC-NSCLC, SCLC-
SQC). Finally, there were no significant differences be-
tween undifferentiated lung cancer, LCNE and carcinoids.
The levels of ProGRP in SCLC patients significantly
correlate with the extent of the disease and the patients’
smoking habit. Once the levels of ProGRP in SCLC pa-
tients were compared according the gender and age, no
significant differences were found (Table 7).
ROC curves were used to analyse the levels of ProGRP
for application at the time of SCLC diagnosis, and to dis-
criminate SCLC from NSCLC and SCLC from metasta-
ses to the lung (Figure 1). The ROC curve of ProGRP
demonstrates the specificities and sensitivities not only
at certain cut-off values but also over the entire range of
values. Due to this, all further calculations were fixed at
95% and 96.8% specificity (the latter of which is the best
selection criterion according to the ROC curve) (Table 8).
The ProGRP cut-off level for benign lung diseases, and
benign lung and mediastinal tumours was 62.69 pg/mL
reaching 95% specificity, while the cut-off value for the
reference group of healthy individuals, benign diseases of
the lung and other organs was 65.89 pg/mL reaching
96.8% specificity (Figure 1).
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TABLE 5
DIFFERENCES BETWEEN THE GROUPS ACCORDING TO PROGRP LEVELS AT THE TIME OF DIAGNOSIS USING
THE MANN-WHITNEY U-TEST





OMLPT ML MTO BTLM BTO BDLO
HEALTHY <10–5 <10–5 4.5´10–2 <10–5 <10–5 4.4´10–3 <10–5 NS 2.6´10–2 NS <10–5
SCLC – <10–5 <10–5 NS <10–5 <10–5 <10–5 <10–5 <10–5 2´10–4 <10–5
NSCLC – NS <10–5 <10–5 NS 9.9´10–3 NS NS NS NS
C – 4´10–4 NS NS NS NS NS NS NS
SCLC-NSCLC – <10–5 <10–5 <10–5 <10–5 <10–5 5.4´10–3 <10–5
UNDIF LC – <10–5 1.4´10–2 <10–5 2´10–4 NS 1´10–4
OMLPT – 3.5´10–3 NS NS NS NS
ML – 4´10–4 4.7´10–3 NS 3.6´10–2
MTO – NS NS NS
BTLM – NS NS
BTO – NS
BDLO –
SCLC – small cell lung carcinoma, NSCLC – non -small cell lung carcinoma, C – carcinoid, UNDIF LC – undifferentiated lung carci-
noma, OMLPT – other malignant lung and pleura tumour, ML – metastases to the lung, MTO – malignant tumour of the other organ,
BTLM – benign lung and mediastinal tumours, BTO – benign tumours of the other organs, BDLO – benign disease of the lung and






































Fig. 2. Sensitivity of ProGRP by main group of malignant diseases at specificity 95% (cut-off 62.69 pg/mL) and 96,8 % (cut-off 65.89
pg/mL). SCLC – small cell lung carcinoma, NSCLC – non -small cell lung carcinoma, C – carcinoid, UNDIF – undifferentiated lung
carcinoma, OMLPT – other malignant lung and pleura tumor, ML – metastases to the lung, MTO – malignant tumor of the other organ.
Using the cut-off values for the reference population,
ProGRP shows to be the marker with the highest sensi-
tivity – 85% for the detection of SCLC followed by 71.43%
in the mixed SCLC-NSCLC type. In patients with a lim-
ited SCLC disease ProGRP sensitivity was 76.71%, while
in the extensive disease 89.76%. However, in the other
studied groups ProGRP seldom revealed a level higher
than the reference range of population, and its sensitiv-
ity was much lower (Figures 2, 3).
Discussion
The clinical application of the ProGRP tumour mar-
ker to identify SCLC can be achieved through a stand-
ardisation process which depends on population charac-
teristics, patient medical histories, the sample size re-
searched, the time of sampling in relation to other diag-
nostic invasive procedures, and the clinically defined
control groups expected to have a different dynamics
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TABLE 6
DIFFERENCES BETWEEN THE MOST SIGNIFICANT SUBGROUPS ACCORDING TO PROGRP LEVELS AT THE TIME OF DIAGNOSIS
USING THE MANN-WHITNEY U-TEST















ED – <10–5 <10–5 <10–5 3.7´10–2 <10–5 <10–5 3´10–4 6.1´10–3 NS NS 1.9´10–2 5.3´10–3 <10–5 <10–5
LD – <10–5 <10–5 NS <10–5 <10–5 3.5´10–2 NS NS NS NS NS <10–5 <10–5
AD – NS 3.1´10–3 NS NS NS NS 8.3´10–3 1.4´10–3 <10–5 3.1´10–2 1´10–4 NS
LCC – 3.5´10–3 NS NS NS NS 1.1´10–2 2.1´10–3 1´10–4 4.7´10–2 4´10–4 NS
LCNE – 1´10–2 7.4´10–3 NS NS NS NS NS NS NS 1.5´10–3
UNDIF
NSCLC
– NS NS NS 1.4´10–2 5´10–3 1´10–4 NS 9.1´10–3 NS
SQC – NS NS 1.3´10–2 2.9´10–3 <10–5 NS 1.9´10–3 NS
AC – NS NS NS 6.6´10–2 NS NS NS
TC – NS NS NS NS NS NS
SCLC-AD – NS NS NS 2.3´10–2 5´10–3
SCLC-LCC – NS NS 2.9´10–3 1.1´10–3
SCLC-
NSCLC
– NS 1´10–4 <10–5
SCLC-SQC – NS 2.2´10–2
UNDIF LC – <10–5
MTO –
SCLC – small cell lung carcinoma, ED – extensive disease SCLC, LD – limited disease SCLC, AD – adenocarcinomas, LCC – large cell
carcinomas, LCNE – large cell neuroendocrine carcinoma, UNDIF – undifferentiated, NSCLC – non-small cell lung carcinoma, SQC –
squamous cell carcinomas, AC – atypical carcinoid, TC – typical carcinoid, UNDIF LC – undifferentiated lung carcinoma, MTO – ma-
lignant tumour of the other organ, NS – nonsignificant
TABLE 7









Nonsmoker 64 1396.85 827.07 3781.78 <10–5**
Former smoker 17 1000.00 145.85 2762.98
Smoker 119 271.83 69.51 1000.00
Male 159 617.19 134.61 1653.29 NS*
Female 41 534.51 96.39 2093.77
Age <65 101 499.21 130.72 1756.54 NS*
Age  65 99 671.47 134.61 1635.14
25th – 25th percentile, 75th – 75th percentile, * p-value determined using the Mann-Whitney U-test, ** p-value determined using the
Kruskal-Wallis ANOVA, NS – nonsignificant
from the healthy population11. The approach to stand-
ardisation in determining the cut-off value of tumour
markers is different from the approach to the standardi-
sation of molecules in normal cell processes. There is no
ideal marker since determining cut-off values is a process
in which all the population variables influencing marker
levels are evaluated. For instance, according to our re-
search there are 79 diseases influencing CYFRA 21–1
levels11. The research examined all the diseases that af-
fect the ProGRP cut-off value. The ProGRP levels mea-
sured can only be viewed as a dynamic value at >95%
specificity. What matters in evaluation is not a single
ProGRP cut-off value but a range of values. It is impor-
tant to enable, direct and encourage clinicians to use the


































LCC TM MES LT ML MTO
95%
96.80%
76.71 89.76 9.4 14.13 3.7 50 15.91 0 33.33 25.0 0 26.88 75 62.5 83.33 70.59 0 0 14.26 7.69 6
100
76.71 89.76 9.4 14.13 3.7 50 15.91 0 33.33 25.0 0 20.43 75 62.5 83.33 70.59 0 0 14.26 7.69 6
SCLC-
NSCLC
Fig. 3. Sensitivity of ProGRP by main subgroups of malignant diseases at specificity 95% (cut-off 62.69 pg/mL) and 96,8 % (cut-off 65.89
pg/mL). SCLC – small cell lung carcinoma, ED – extensive disease SCLC, LD – limited disease SCLC, AD – adenocarcinomas, LCC –
large cell carcinomas, LCNE – large cell neuroendocrine carcinoma, UNDIF – undifferentiated, NSCLC – non-small cell lung carci-
noma, SQC – squamous cell carcinomas, AC – atypical carcinoid, TC – typical carcinoid, C – carcinoid, TM – tumor of the mediasti-
num, MES – mesothelioma, LT – lymphoproliferative tumors, ML – metastases to the lung, MTO – malignant tumor of the other organ.
TABLE 8
DATA FROM ROC CURVES CONSTRUCTED FOR OPTIMISING PROGRP CUT-OFF VALUES TO REACH








H/BDLO/SCLC 273/130/200 96.8 85 65.89*
BDL/BTLM/SCLC 124/39/200 96.9 84.5 67.94*
NSCLC/SCLC 294/200 88.1 85 66.98*
ML/SCLC 91/200 97.8 83.5 73.65*
H/BDLO/SCLC 273/130/200 95 85.8 60.40
BDL/BTLM/SCLC 124/39/200 95 85 62.69
NSCLC/SCLC 294/200 95 56 428.74
ML/SCLC 91/200 95 84.5 68.01
H/BDLO/SCLC 273/130/200 100 71 165
BDL/BTLM/SCLC 124/39/200 100 71 165
NSCLC/SCLC 294/200 100 0 70128
ML/SCLC 91/200 100 74 138.4
H – healthy, BDLO – benign disease of the lung and other organs, SCLC – small cell lung carcinoma, BDL – benign disease of the lung,
BTLM – benign lung and mediastinal tumours, NSCLC – non -small cell lung carcinoma, ML – metastases to the lung, * the most accu-
rate criterion of the ROC curve
marker in early SCLC diagnosis. The high sensitivity of
ProGRP at 85% in our study facilitates this. It was par-
ticularly important to research the influence of all the
benign and malignant diseases appearing in differential
diagnosis and causing problems for the clinical applica-
tion of markers. ROC curves were constructed, and at
95% specificity in the reference group of benign lung dis-
eases with benign lung tumours and mediastinum the
cut-off value of ProGRP was 62.69 pg/mL. Healthy sub-
jects and patients with benign diseases of the lung and
other organs at 96.8% specificity defined the cut-off value
of ProGRP at 65.89 pg/mL as the most accurate criterion
of the ROC curve indicating SCLC. Tumour markers of-
fer some advantages in relation to other biological vari-
ables in making a diagnosis. They are specific molecules,
different dosages and are reproducible in immunoassays.
The better the sensitivity-specificity relationship, the
sooner markers can be introduced into clinical practice,
as suggested by clinicians. Our study of ProGRP shows
that high values of both sensitivity and specificity point
to SCLC at 65.89 pg/mL. High serum levels of ProGRP
could be regarded as a value that indicates SCLC in
known lung cancer phenotypic heterogeneity. In particu-
lar, according to our findings, the level of ProGRP above
the cut-off value of 65.89 pg/mL and imaging findings
having detected pulmonary infiltrates most probably re-
flect biological SCLC tumour behaviour that requires
further clinical diagnostic confirmation. Regardless of
the efforts to contribute to diagnosis with markers, their
application remains questionable until the diagnosis
made is confirmed by standard clinical methods. The ap-
plication of clinical molecular biomarkers, besides mark-
ers such as ProGRP, will accelerate SCLC detection.
ProGRP provides important insight into the neuro-
endocrine differentiation of lung cancer, particularly in
SCLC, SCLC-NSCLC, undifferentiated lung carcinoma
and carcinoids. The sensitivity of ProGRP in these
groups was higher than in all the other groups. This has
been brought into relation with the fact that ProGRP
levels and the extent of its release are very low in benign
diseases and malignant lung tumours other than SCLC.
Only the smallest amounts of this marker are released in
these. Unknown pulmonary infiltrates without any clini-
cal confirmation of them being SCLC and with an ele-
vated level of ProGRP are an exception in our study. And
these infiltrates are uterine cancer and larynx cancer
from the group of malignant tumours of other organs, as
well as dermatomes from the group of benign tumours of
other organs. These two groups showed great differences
in maximum levels (1219 pg/mL and 85 pg/mL). The fact
that the first group were patients without SCLC having
been confirmed and that the second group comprising
benign tumours of other organs was made up of a very
small number of patients cannot be ignored.
To support the diagnosis of SCLC for the purpose of
more efficient therapeutic stratification, whether in
overall, limited stage, extensive stage or mixed type lung
cancer at high specificity (100%), it is essential to analyse
a much larger sample of SCLC without great discrepan-
cies in the number of subjects tested in each group.
And now ProGRP assays cost as much as molecular
markers for SCLC.
This research has proven ProGRP to be a sensitive
marker for 85% of SCLC patients. The rate of SCLC de-
tection with ProGRP has been in agreement with other
authors. Between 1994 and 2008 its sensitivity ranged
between 41% and 100% at 90% to 99% specificity8–24. The
results depended on the groups selected for specificity.
The reference population used for specificity comprised
healthy persons and patients with benign diseases of the
lung and other organs. Our specificity was high (96.8%)
and facilitated the detection of SCLC, SCLC-NSCLC and
SCLC in undifferentiated lung cancer. Previous studies
also showed that ProGRP is a superior marker for
SCLC13,25. For the purpose of differentiating lung tu-
mours of unknown origin the discriminative power of
ProGRP was shown by a ROC curve on data on SCLC
and metastasis to the lung. Although the cut-off value
based on this curve is similar to our selected cut-off
value, applying it in clinical practice is difficult knowing
the biology of metastases including ProGRP which de-
pends on the organ from which the metastases origi-
nated. According to different studies, cut-offs (or refer-
ence levels) have been reported to range between 16.6
and 87 pg/mL depending on the referent population8–24.
Our reference level of 65.98 pg/mL facilitated the detec-
tion of SCLC with a positive and negative predictive
value of 92.6%. Furthermore, our results prove that
ProGRP correlates with the extent of the disease, which
is in concordance with the findings of others authors13,17.
Obviously, ProGRP is involved in SCLC cell growth stim-
ulation.
The study of the further evaluation of ProGRP in lon-
gitudinal follow-ups in SCLC therapy and in cerebral
neuroendocrine tumours is in progress.
If the level of ProGRP in NSCLC patients exceeds 400
pg/mL, their clinical-pathological future must be exam-
ined with regard to either SCLC (it might in fact be
NSCLC-SCLC) or neuroendocrine differentiation (inclu-
ding the extensive stage of the disease).
It is still debatable whether a diagnosis can be made
or not according to marker values, particularly in border-
line cases. Accordingly, ProGRP levels are evaluated indi-
vidually in each patient as a dynamic value within the
context of the clinical parameters known and defined for
this marker as stated in the referral. Finally, repeated
standard diagnostic methods have not disproved but only
confirmed our findings in terms of marker level interpre-
tation.
Conclusion
ProGRP is a tumour marker for the detection of
SCLC. Its level at the time of diagnosis indicates the
presence of SCLC, later confirmed by standard clinical
procedures. Its cut-off is 65.89 pg/mL at 96.8% specificity.
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ProGRP is a useful marker provided it contributes to
the clinical methods used for diagnosis differentiating
between SCLC and NSCLC, primary tumour of the lung
and metastasis to the lung from other organs.
High levels of ProGRP in undifferentiated lung can-
cer are most probably connected with the neuroendocri-
ne biological activity of SCLC.
In NSCLC and carcinoids elevated ProGRP levels are
most probably the consequence of neuroendocrine differ-
entiation. This requires special attention by any future
research.
Extremely high levels of ProGRP indicate a meta-
stasised advanced disease.
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ODRE\IVANJE REFERENTNE RAZINE PRO-GASTRIN OTPU[TAJU]EG PEPTIDA (PROGRP)
KOD RAKA PLU]A U SKLADU S POPULACIJSKIM KARAKTERISTIKAMA
S A @ E T A K
Odre|ivanje razine tumorskog markera u grupama populacije koje su povezane s biologijom markera u normalnoj i
tumorskoj stanici dio je standardizacijskog procesa koji omogu}uje klini~ku primjenu. Razina pro-gastrin otpu{taju}eg
peptida (ProGRP) je izmjerena u serumu 273 zdrava ispitanika, 176 pacijenata s benignim bolestima i tumorima, 200
pacijenata s karcinomom plu}a malih stanica (SCLC), 294 s karcinomom nemalih stanica plu}a (NSCLC), 21 s karcinoi-
dom, 93 s nediferenciranim rakom plu}a, 35 s mje{anim SCLC-NSCLC i 189 s drugim malignitetima. Razina ProGRP je
zna~ajno vi{a kod pacijenata SCLC i mje{anog tipa SCLC-NSCLC u odnosu na sve ostale istra`ene grupe (p<5,4 ´ 10–3).
Kod SCLC pacijenata razina ProGRP zna~ajno korelira s pro{ireno{}u bolesti i pu{enjem. Referentna razina (engl.
cut-off) ProGRP iznosi 65,89 pg/mL kod SCLC u Hrvatskoj populaciji. Bazira se na specifi~nosti od 96,8% kod benignih
bolesti koje uobi~ajeno predstavljaju problem u diferencijalnoj dijagnozi. U vrijeme dijagnoze SCLC senzitivnost ProGRP
je 85%.
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